Related by context. All words. (Click for frequent words.) 77 rituximab refractory follicular 75 previously untreated follicular 71 relapsed MM 69 demonstrated antitumor activity 69 stage IIIb IV 68 recurrent glioblastoma multiforme 68 hA# 68 CHOP chemotherapy 68 Relapsed Refractory 68 relapsed refractory aggressive 68 null responder 68 stage IIIb 68 galiximab 68 leukemia AML 67 leukemia CLL 67 heavily pretreated 67 relapsed refractory 67 gemcitabine carboplatin 67 indolent NHL 67 relapsed multiple myeloma 67 antiretroviral naïve 67 bortezomib refractory 67 undergoing hematopoietic stem 66 mRCC 66 Amgen Neulasta R 66 cyclophosphamide doxorubicin vincristine 66 recurrent glioblastoma 66 multiple myeloma MM 66 plus dexamethasone 66 metastatic renal cell carcinoma 66 achieved sustained virological 66 EGFR mutation positive 66 CVP cyclophosphamide vincristine 66 underwent resection 66 de novo kidney transplant 66 small lymphocytic lymphoma 66 HBeAg + 66 unresectable tumors 66 refractory metastatic 66 refractory CLL 66 chlorambucil 66 mitoxantrone plus 66 alfa 2a 65 relapsed refractory multiple myeloma 65 imatinib Gleevec ® 65 achieved CCyR 65 naïve HCV 65 Amgen Neulasta ® 65 Flu Cy 65 pegylated interferon alfa 65 FUSILEV enhances 65 BARACLUDE ® 65 8mg/kg 65 Diffuse Large B 65 methotrexate monotherapy 65 serologically active systemic lupus 65 bendamustine 65 autoantibody positive 65 Doxil ® 65 recurrent NSCLC 65 steroid refractory 65 nonmetastatic 65 HIV coinfected 65 psoriatic arthritis PsA 65 antiangiogenic therapy 65 haematologic malignancies 65 refractory NSCLC 65 treatment naive genotype 65 relapsed indolent NHL 65 follicular lymphomas 64 interferon ribavirin 64 refractory cutaneous T 64 treatment naïve genotype 64 HBeAg positive patients 64 recurrent malignant glioma 64 antiretroviral naive 64 VELCADE melphalan 64 neovascular diseases 64 indolent lymphoma 64 SPRYCEL ® 64 T1c 64 pegylated alpha interferon 64 Pegasys peginterferon alfa 2a 64 oblimersen 64 decompensated liver disease 64 plus prednisone 64 standard chemotherapy regimen 64 receiving highly emetogenic 64 receiving VELCADE 64 HER2 positive metastatic breast 64 Cutaneous T 64 lenalidomide Revlimid R 64 cisplatin gemcitabine 64 KRAS mutations occur 64 paclitaxel Taxol R 64 maximally tolerated lipid lowering 64 infliximab monotherapy 64 docetaxel Taxotere ® 64 deep venous thromboses 64 anthracycline taxane 64 DOXIL ® 64 dasatinib Sprycel 64 null responder HCV 64 certolizumab 64 stage IIIB 64 CCR5 tropic HIV 64 hepatitis C genotype 64 perioperatively 64 ribavirin RBV 64 anthracyclines taxanes 64 refractory chronic lymphocytic 64 Newly Diagnosed Multiple Myeloma 64 sorafenib Nexavar 64 Aflibercept 64 relapsing remitting MS RRMS 64 refractory chronic myeloid 64 metastatic malignant 64 relapsed SCLC 64 Relapsed Refractory Aggressive 64 non splenectomized 64 HBeAg negative patients 64 vincristine doxorubicin 64 metastatic GIST 64 FOLFOX4 63 asymptomatic metastatic 63 heavily pretreated patients 63 SNT-MC#/idebenone 63 adalimumab Humira 63 metastatic gastric 63 CYT# potent vascular disrupting 63 superficial bladder cancer 63 ritonavir boosted 63 Temodar ® 63 achieved sustained virologic 63 Gleevec resistant 63 fludarabine cyclophosphamide 63 Non Hodgkin 63 refractory CTCL 63 Rituxan rituximab 63 chronic lymphocytic leukemia CLL 63 thalidomide Thalomid 63 unresectable stage 63 dacarbazine DTIC 63 Castration Resistant Prostate Cancer 63 smoldering myeloma 63 gefitinib Iressa 63 follicular NHL 63 metastatic renal 63 Heterozygous Familial Hypercholesterolemia 63 achieve sustained virologic 63 Hormone Refractory Prostate Cancer 63 dasatinib Sprycel ® 63 Albuferon TM 63 forodesine 63 Hodgkin lymphoma HL 63 MabThera Rituxan 63 adult chronic ITP 63 ACTEMRA TM 63 adriamycin 63 opioid naive 63 hypercholesterolemic patients 63 basiliximab 63 Follicular Lymphoma 63 pegylated interferon alfa 2a 63 bacillus Calmette Guerin 63 lumiliximab 63 Fludarabine 63 patients coinfected 63 DEB# 63 advanced hepatocellular carcinoma 63 relapsed CLL 63 relapsing multiple sclerosis 63 adverse cytogenetics 63 hormone refractory metastatic prostate 63 achieved ACR# 63 indolent follicular non 63 Relapsed 63 Relapsing Remitting Multiple Sclerosis 63 paclitaxel cisplatin 63 pegylated interferon alpha 63 trastuzumab Herceptin R 63 peginterferon alpha 2a 63 STELARA ® 63 recurrent genital herpes 63 imatinib Gleevec 63 oropharyngeal candidiasis OPC 63 mycophenolate mofetil MMF 63 chronic HCV 63 refractory indolent non 63 lymphoid malignancies 63 AVASTIN 63 biliary tract cancer 63 chronic HBV 63 minimally symptomatic 62 Pemetrexed 62 candidemia 62 HBeAg positive 62 DOXIL 62 gemcitabine Gemzar 62 MCyR 62 metastatic renal cell 62 systemic anaplastic large 62 erlotinib Tarceva ® 62 myelodysplastic myeloproliferative diseases 62 chronic HCV genotype 62 essential thrombocythemia ET 62 haematologic 62 fallopian tube carcinoma 62 GvHD 62 pegylated liposomal doxorubicin 62 advanced medullary thyroid 62 chronic hepatitis B. 62 cyclophosphamide chemotherapy 62 refractory acute myeloid 62 REYATAZ r arm 62 Naive Patients 62 severe hepatic dysfunction 62 ribavirin therapy 62 nucleoside naive 62 hepatorenal syndrome 62 Pegasys ® 62 Platinol ® 62 myeloid metaplasia 62 thetreatment 62 completely resected 62 refractory Hodgkin 62 plus prednisone prednisolone 62 recurrent glioma 62 Myelodysplastic Syndrome MDS 62 recurrent GBM 62 cytogenetic responses 62 stage IIIB IV 62 ® lenalidomide 62 oral clodronate 62 Genasense ® 62 chronic GVHD 62 partial remissions 62 CVP chemotherapy 62 ZACTIMA 62 ErbB2 positive 62 follicular Non Hodgkin 62 docetaxel chemotherapy 62 relapsed acute lymphoblastic 62 Waldenstrom macroglobulinemia 62 trastuzumab Herceptin ® 62 CIMZIA ™ 62 Pegylated Interferon 62 HIV HCV coinfected 62 FOLFIRI alone 62 Stage IIB 62 metastatic pancreatic 62 recurrent metastatic 62 Folfox 62 Campath alemtuzumab 62 TTF Therapy 62 plus COPEGUS 62 irinotecan chemotherapy 62 nondiabetic patients 62 cyclophosphamide methotrexate 62 antirheumatic 62 daily Infergen 62 MabCampath 62 mcg BID 62 vinorelbine 62 CRp 62 CIMZIA TM certolizumab pegol 62 CLL SLL 62 Ph + acute lymphoblastic 62 refractory myeloma 62 diagnosed Ph + 62 PegIFN RBV 62 Chronic Lymphocytic Leukemia CLL 62 moderate renal impairment 62 visceral metastases 62 de novo AML 62 mCRPC 62 mg/m2 dose 62 azacytidine 62 refractory colorectal cancer 62 hepatic metastases 62 relapsed refractory AML 62 histologically confirmed 62 Chronic Hepatitis C 62 Patients Treated With 62 evaluating tivozanib 62 Patients Receiving 62 naive HCV 62 cilengitide 62 cisplatin chemotherapy 62 immune thrombocytopenic purpura ITP 62 non metastatic osteosarcoma 62 idiopathic thrombocytopenic purpura ITP 62 metastatic CRC 62 underwent surgical resection 62 metastatic hormone refractory 62 anthracycline containing 62 leukemia ALL 61 progressive PsA 61 neutropenic sepsis 61 paclitaxel Taxol ® 61 radiotherapy RT 61 mutated KRAS 61 primary immunodeficiency PI 61 Platinol ® cisplatin 61 concomitantly administered 61 Cell Lymphoma 61 overactive bladder syndrome 61 BCG refractory 61 metastatic colorectal carcinoma 61 acute lymphoblastic 61 4mg/kg 61 receiving XGEVA 61 colorectal liver metastases 61 FluCAM 61 voriconazole 61 mg administered orally 61 humanized interleukin 6 61 idiopathic thrombocytopenic purpura 61 NMIBC 61 stage IIIA 61 invasive aspergillosis 61 pancreatic NET 61 HBeAg positive chronic hepatitis 61 neutropenia dehydration dyspnea 61 everolimus tablets 61 invasive candidiasis 61 Relapsed Refractory Multiple Myeloma 61 Hodgkin lymphoma NHL 61 GW# [003] 61 Telintra 61 LHRH receptor positive 61 CCyR 61 Peginterferon 61 mild renal insufficiency 61 TORISEL 61 sustained virological response 61 Complicated Skin 61 5-FU/LV 61 estramustine 61 Refractory Hodgkin Lymphoma 61 APTIVUS R 61 sorafenib Nexavar ® 61 HBeAg negative 61 CR nPR 61 acute GvHD 61 Kit CD# positive 61 FOLFOX6 61 fistulizing Crohn disease 61 ZOLINZA 61 metastatic malignant melanoma 61 lamivudine refractory patients 61 peginterferon alfa 2a #KD 61 interleukin IL -# 61 severe exacerbations 61 refractory follicular 61 genitourinary GU 61 Advanced Melanoma 61 fluticasone salmeterol 61 5 Fluorouracil 61 thrombocytopenic 61 relapsed ovarian cancer 61 Soft Tissue Sarcoma 61 imatinib resistant 61 Kaplan Meier estimate 61 Engerix B 61 Quinamed 61 relapsed leukemia 61 underwent liver transplantation 61 trabectedin 61 splenectomized 61 PREZISTA r 61 efavirenz EFV 61 castrate resistant prostate cancer 61 OHR/AVR# 61 potentially hepatotoxic 61 taxane chemotherapy administered 61 immunocompetent 61 gemcitabine Gemzar ® 61 taxane therapy 61 MAGE A3 ASCI 61 plus methotrexate 61 receiving TNF blockers 61 antithymocyte globulin 61 melphalan prednisone 61 immune thrombocytopenic purpura 61 Irinotecan 61 Cell Lymphoma CTCL 61 achieved PASI 61 salmeterol fluticasone 61 esophageal candidiasis 61 KRAS wild 61 Natalizumab 61 cyclophosphamide FC 61 temsirolimus Torisel 61 chronic HCV infection 61 tipranavir r 61 unstable angina UA 61 cell lymphoma CTCL 61 Golimumab 61 complete remissions 61 Rate ORR 61 splenectomized patients 61 DLBCL 61 relapsed AML 61 ovarian carcinoma 61 Pharmacokinetics PK 61 #mg ATC 61 metastatic CRPC 61 locoregional disease 61 relapsed Hodgkin lymphoma 61 chronic hemodialysis 61 tolterodine ER 61 evaluating REVLIMID 61 selective modulator 61 nilotinib Tasigna 61 prednisone prednisolone plus 61 lintuzumab SGN 61 Solid Tumors 61 KRAS mutant tumors 61 IOP lowering 60 FluCAM arm 60 coinfected 60 cinacalcet 60 Fludara 60 elacytarabine 60 radioimmunotherapeutic agent 60 chemotherapy docetaxel 60 Aptivus ® 60 HCV genotype 1 60 progression TTP 60 metastatic kidney 60 relapsed mantle 60 FOLFOX chemotherapy 60 tumor lysis syndrome 60 5 FU leucovorin 60 CIMZIA TM 60 Navelbine ® 60 R entecavir 60 toenail onychomycosis 60 systemic ALCL 60 mCRC patients 60 unresectable Stage III 60 FOLFOX regimen 60 prostate cancer HRPC 60 systemic invasive fungal 60 alkylating agent 60 hypereosinophilic syndrome 60 Treatment Naive Patients 60 receptor tyrosine kinase inhibitor 60 cutaneous T 60 aflibercept VEGF Trap 60 Adjuvant chemotherapy 60 BENICAR HCT 60 primary hypercholesterolemia 60 pancreatic neuroendocrine tumors 60 rituximab Rituxan 60 CML CP 60 Antitumor Activity 60 cytarabine daunorubicin 60 resected pancreatic cancer 60 RoACTEMRA 60 temozolomide TMZ 60 non CF bronchiectasis 60 Chronic Myelogenous Leukemia CML 60 combination antiretroviral therapy 60 acute STEMI 60 TMC# r 60 doublet chemotherapy 60 histologies 60 castration resistant hormone refractory 60 Acute Coronary Syndromes ACS 60 CINQUIL 60 lymphocytosis 60 interferon alfa 2a 60 antibody MAb 60 Dementia Related Psychosis 60 pegylated interferon alfa 2b 60 micafungin 60 lymphoma CTCL 60 biochemical relapse 60 Cell Non Hodgkin 60 hemodialysis patients 60 erythematosus SLE 60 leukemia APL 60 infliximab Remicade 60 carboplatin chemotherapy 60 IMiDs ® 60 refractory multiple myeloma 60 adefovir dipivoxil 60 metastatic RCC 60 commercialize deforolimus 60 locoregional recurrence 60 low dose cytarabine 60 evaluable 60 Arranon 60 5 fluorouracil leucovorin 60 FOLFIRI 60 Fludara ® 60 Omacetaxine 60 abacavir lamivudine 60 bortezomib Velcade R 60 Gemzar ® 60 nicardipine 60 dacarbazine 60 PROSTVAC VF 60 pegfilgrastim 60 follicular lymphoma 60 liposomal amphotericin B 60 allogeneic HSCT 60 pamidronate 60 Juvenile Idiopathic Arthritis 60 preoperative chemotherapy 60 Peg IFN 60 Paraplatin ® carboplatin 60 EOquin TM 60 HERCEPTIN 60 patients evaluable 60 viral kinetics 60 fluvastatin 60 pT2 60 xenograft models 60 ISTODAX ® 60 Nothing Wadden 60 tumors GIST 60 milatuzumab 60 Certolizumab pegol 60 ascending dose 60 Myelodysplastic Syndrome 60 mCRC acneform rash 60 mycophenolate mofetil 60 mild hepatic impairment 60 taxane chemotherapy 60 interferon alfa 2b 60 epirubicin cyclophosphamide 60 chronic immune thrombocytopenic 60 gastrointestinal stromal tumors GIST 60 pancreatic adenocarcinoma 60 riociguat 60 hoFH 60 XL# administered orally 60 alvespimycin 60 alpha 2a 60 pancreatic carcinoma 60 metastatic neuroendocrine tumors 60 tipranavir ritonavir 60 multivessel coronary artery 60 Rituximab 60 allogeneic bone marrow 60 prostate cancer CRPC 60 vinca alkaloid 60 SSc 60 AML MDS 60 HLA DR2 60 TroVax ® 60 amrubicin 60 BENICAR 60 PEGINTRON TM 60 CPOP R 60 rituximab 60 eosinophilic asthma 60 evaluating mipomersen 60 plus dacarbazine 60 patientswith 60 LymphoStat B belimumab 60 pediatric acute lymphoblastic 60 cetuximab Erbitux R 60 Rheumatoid Arthritis RA 60 pT3 60 adefovir treated 60 pomalidomide 60 cisplatin vinorelbine 60 hematologic malignancy 60 histologically proven 60 colorectal cancer liver metastases 60 peginterferon alfa 2a Pegasys 60 anti arrhythmic drug 60 chronic ITP patients 60 sunitinib malate 60 dexamethasone Decadron 60 bone marrow reticulin deposition 60 prednisolone chemotherapy 60 ribavirin Copegus ® 60 docetaxel prednisone 60 HBeAg negative chronic hepatitis 60 Epratuzumab 60 Temsirolimus 60 smoldering multiple myeloma 60 achieve sustained virological 60 cancer mCRC 60 PREZISTA r arm 60 non squamous histology 60 Surgical resection 60 chronic periodontitis 60 advanced carcinoid 60 Ribavirin causes 60 ara C 60 atypical hemolytic uremic syndrome 60 imatinib therapy 60 PEG IFN 60 MGd 60 imatinib mesylate Gleevec 60 HCV infected 60 refractory AML 60 non resectable 60 venlafaxine XR 60 e antigen HBeAg 60 diagnosed multiple myeloma 60 baminercept 60 receiving VICTRELIS 60 dopamine partial agonist 60 idarubicin 60 ß blockers 60 untreated CLL 60 cetuximab Erbitux ® 59 malignant ascites 59 crizotinib PF # 59 RECIST Response Evaluation Criteria 59 alefacept 59 IBS C 59 docetaxel Taxotere 59 INFERGEN 59 Ophena TM 59 cytogenetic response 59 RECIST criteria 59 NATRECOR ® 59 acute myeloid 59 adjuvant cisplatin 59 relapsing MS 59 neoadjuvant radiation 59 hyperphenylalaninemia HPA due 59 ALIMTA cisplatin 59 Sipuleucel T 59 ER CHOP 59 BRAF V# mutation 59 dual endothelin receptor antagonist 59 ORENCIA ® 59 cell carcinoma RCC 59 Chronic lymphocytic leukemia 59 pertuzumab 59 Myelofibrosis 59 Peginterferon alfa 2b 59 neoadjuvant treatment 59 LEUKINE 59 drotrecogin alfa activated 59 PEGylated Fab fragment 59 sunitinib Sutent 59 TO AVOID PREGNANCY WHILE 59 KRAS status 59 mapatumumab 59 dose escalation phase 59 CTAP# Capsules 59 valsartan amlodipine 59 opioid induced constipation OIC 59 kidney urologic 59 CTAP# 59 CR CRu 59 papillary renal cell carcinoma 59 Tarceva TM 59 APTIVUS r 59 metaglidasen 59 transplantation HCT 59 bevacizumab Avastin ® 59 dalteparin 59 constipation OIC 59 REYATAZ ® 59 MALT lymphoma 59 FOLFOX6 chemotherapy regimen 59 Genentech Rituxan 59 prospectively stratified 59 hepatitis C HCV 59 CHOP cyclophosphamide doxorubicin vincristine 59 either acutely decompensated 59 metastatic bladder 59 oral vancomycin 59 carboplatin paclitaxel 59 debulking surgery 59 febrile neutropenia 59 Myelodysplastic syndromes MDS 59 denileukin diftitox 59 PEGylated interferon beta 1a 59 induce remission 59 etanercept Enbrel 59 vidofludimus 59 sunitinib Sutent ® 59 histological subtypes 59 Advanced Solid Tumors 59 leukemia multiple myeloma 59 PEG interferon 59 lymphomas leukemias 59 undergoing peritoneal dialysis 59 PSA nadir 59 advanced metastatic renal 59 anti angiogenic agents 59 active ankylosing spondylitis 59 FLT3 ITD 59 pediatric Crohn disease 59 polycythemia vera essential thrombocythemia 59 Mitomycin C 59 aMCI precursor 59 purpura ITP 59 Pertuzumab 59 macroglobulinemia 59 panobinostat 59 post herpetic neuralgia PHN 59 hematological malignancy 59 Blinatumomab 59 localized renal 59 anagrelide 59 Copegus ribavirin 59 follicular B 59 FIRMAGON 59 castration resistant prostate cancer 59 Plaquenil 59 ORENCIA R 59 conventional DMARDs 59 MACUGEN 59 receiving CIMZIA #mg 59 genotype 1b 59 azacitidine 59 metastatic uveal melanoma 59 oral deforolimus 59 mycosis fungoides 59 oral antidiabetic medication 59 BCR ABL inhibitor 59 antimetabolite 59 protease inhibitor PI 59 recurrent glioblastoma multiforme GBM 59 inhaled bronchodilators 59 calcineurin inhibitor 59 Cimzia TM 59 HCV Genotype 59 lopinavir ritonavir Kaletra 59 Virulizin ® 59 refractory gout 59 dosing cohort 59 folinic acid 59 situ CIS 59 MyVax R 59 xanthine oxidase inhibitor 59 PKC# 59 rimonabant #mg/day 59 HCV RESPOND 2 59 angiographic outcomes 59 Nilotinib 59 temozolomide Temodar 59 tyrosine kinase inhibitor TKI 59 q#h 59 neutropaenia 59 differentiated thyroid 59 humanized therapeutic 59 chemoradiation therapy 59 Vincristine 59 briakinumab 59 oral hypoglycemic agent 59 NeuroStar TMS Therapy 59 malignant pleural mesothelioma MPM 59 anastrazole 59 basal bolus regimen 59 follicular lymphoma FL 59 nilotinib 59 atazanavir ritonavir 59 complete cytogenetic response 59 comparator arm 59 Intravenous immunoglobulin 59 Paroxysmal Nocturnal Hemoglobinuria PNH 59 Atypical Hemolytic Uremic Syndrome 59 posaconazole 59 allogeneic stem cell 59 LANTUS ® 59 TNF alpha antagonist 59 hematopoietic cancers 59 HBeAg 59 linaclotide treated 59 Glioblastoma Multiforme 59 receiving FUSILEV 59 gemcitabine cisplatin 59 fluorouracil leucovorin 59 Secondary endpoints include 59 receiving golimumab 59 enzastaurin 59 adalimumab etanercept 59 adjunctive placebo 59 acute leukemias 59 basal cell carcinoma BCC 59 operable breast cancer 59 Gleevec imatinib 59 Free Survival PFS 59 immunosuppressive regimen 59 #mg/m# [001] 59 preoperative PSA 59 Chronic Myelogenous Leukemia 59 pretransplant 59 LymphoStat B TM 59 refractory CML 59 PI3K/Akt pathway inhibitor 59 Metastatic Colorectal Cancer 59 3mg/kg 59 chemotherapy cisplatin 59 % CI #.#-#.# [007] 59 Pegylated Liposomal Doxorubicin 59 sorafenib tablets 59 relapsed Acute Myeloid 59 microbiological eradication 58 taxane refractory 58 relapsed ALL 58 metastatic androgen independent 58 elevated LDH 58 HCV genotype 58 using lactulose concomitantly 58 finasteride Proscar 58 aldosterone antagonists 58 imipenem 58 plus gemcitabine 58 Kepivance 58 dose escalation clinical 58 GOUT 58 aromatase inhibitor AI 58 neurologic progression 58 Tarceva erlotinib 58 PsA 58 chronic lymphocytic 58 Xelox 58 prednisone prednisolone 58 included exfoliative dermatitis 58 remission induction 58 Xeloda capecitabine 58 oral diclofenac 58 Traficet EN 58 bivalirudin alone 58 Xeloda ® 58 refractory metastatic colorectal cancer 58 -#.# log# copies mL 58 Elotuzumab 58 vinorelbine tartrate 58 ® bortezomib 58 #mg BID [001] 58 Fluorouracil 58 cell malignancies 58 5-fluorouracil/leucovorin 58 oral talactoferrin 58 Pegasys plus Copegus 58 docetaxel Taxotere R 58 YONDELIS 58 B CLL 58 non resectable metastatic 58 diabetes mellitus DM 58 generalized edema 58 Pegylated interferon 58 IMiDs ® compound 58 Brentuximab Vedotin SGN 58 resistant hormone refractory 58 Raptiva r 58 severe renal impairment 58 ribavirin USP 58 HBeAg seroconversion 58 liver histology 58 HCV SPRINT 58 systemic juvenile idiopathic 58 CANCIDAS 58 efaproxiral 58 FASLODEX 58 anti EGFR antibody 58 Alequel 58 MYCAMINE 58 refractory SCLC 58 TKI therapy 58 REVLIMID R 58 % CI #.#-#.# [003] 58 untreated multiple myeloma 58 davunetide intranasal AL 58 dimeglumine 58 PLX STROKE targeting 58 immunomodulatory therapy 58 molecular remissions 58 veltuzumab 58 evaluating Xcytrin 58 Solid Tumors criteria 58 squamous histology 58 receiving ISENTRESS 58 INSPIRE Trial Phase III 58 NATRECOR R 58 ELACYT 58 hematologic disorders 58 chronic myeloid 58 interferon gamma 1b 58 REYATAZ R 58 Relapsing remitting MS 58 axitinib 58 everolimus eluting stents 58 immuno compromised patients 58 anti leukemic 58 Zometa hazard 58 coinfected patients 58 dermatologic reactions 58 azilsartan medoxomil 58 piperacillin tazobactam 58 Insulin detemir 58 heparin induced thrombocytopenia 58 subependymal giant cell 58 chemoradiotherapy 58 liposomal doxorubicin 58 elevated troponin 58 postoperative chemotherapy 58 assessing T DM1 58 mixed hyperlipidemia 58 Abbott HUMIRA 58 placebo dexamethasone 58 huN# DM1 58 TNF antagonist 58 pyridostigmine 58 via intradermal injections 58 castrate resistant 58 NYP-NEWS 58 oral Hycamtin 58 Trastuzumab 58 Gleevec Glivec 58 AZT zidovudine Retrovir 58 Peginterferon Alfa 2a 58 allogeneic transplantation 58 HoFH 58 seroprotection 58 CALGB # [002] 58 Response Evaluation Criteria 58 PEGylated anti 58 visilizumab 58 Combination therapy 58 ixabepilone 58 boosted protease inhibitor 58 radiolabeled TM# 58 aspirin clopidogrel 58 BEXXAR Therapeutic Regimen 58 Retreatment 58 radiochemotherapy 58 weekly subcutaneous injections 58 pegylated interferons 58 COPAXONE R 58 Tipranavir 58 atherothrombotic events 58 Abrupt discontinuation 58 Gliadel Wafer 58 progressive psoriatic arthritis 58 KETEK 58 FOLFOX 58 TMP SMX 58 clinically localized prostate 58 HCV genotypes 58 telaprevir dosed 58 euthyroid 58 evaluable patients 58 Previously Treated 58 docetaxel Injection Concentrate 58 Vidaza azacitidine 58 IV NSCLC 58 Camptosar ® 58 meropenem 58 Philadelphia Chromosome Positive 58 nonmetastatic prostate cancer 58 abacavir Ziagen 58 rALLy clinical trial 58 undetectable HBV DNA 58 known sulfonamide allergy 58 Arzerra ofatumumab 58 fludarabine 58 Etanercept 58 tenecteplase 58 immune globulin intravenous 58 caspofungin 58 refractory ovarian cancer 58 relapsing remitting multiple sclerosis 58 non myeloid malignancies 58 octreotide LAR 58 acute promyelocytic leukemia APL 58 leukotriene receptor antagonists 58 symptomatic hyponatremia 58 cholangiocarcinoma 58 desvenlafaxine succinate 58 Raptiva ® 58 MKC# MT 58 #I TM# 58 Hematologic toxicity 58 NSTE ACS 58 blastic phase 58 Neoadjuvant 58 pancreatic resection 58 peginterferon alfa 58 Cyclophosphamide 58 recurrent herpes labialis 58 EGFR tyrosine kinase inhibitor 58 Teriflunomide 58 goserelin 58 Relapsing Multiple Sclerosis 58 hemodynamically significant 58 FOLPI 58 rheumatoid arthritis psoriatic arthritis 58 Vidaza ® 58 nab paclitaxel 58 pain palliation 58 titrated glipizide 58 Bayer HealthCare Onyx Pharmaceuticals